Lyra Therapeutics Newsroom

Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial Outcomes

TipRanksNov 14 19:19

BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating

Futu NewsNov 13 19:36

Lyra Therapeutics Analyst Ratings

BenzingaAug 15 19:04

HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target

BenzingaAug 15 19:04

BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating

Futu NewsAug 15 18:31

Lyra Therapeutics Analyst Ratings

BenzingaJun 21 01:40

Jefferies Cuts Lyra to Hold in Wake of Failed Phase 3 Study

Seeking AlphaMay 7 23:14

HC Wainwright & Co. : The Lyra Therapeutics (LYRA.US) rating was downgraded from buy to neutral, and the target price was $2.00.

Zhitong FinanceMay 7 21:51

Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50

MT NewswiresMay 7 19:41

Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)

TipRanksMay 7 17:25

Sell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding Concerns

TipRanksMay 7 17:21

BTIG Downgrades Lyra Therapeutics (LYRA) to a Hold

TipRanksMay 6 23:00

Buy Rating Affirmed for Lyra Therapeutics Amid Strong Phase 3 Prospects for LYR-210

TipRanksMay 2 20:26

Lyra Therapeutics Analyst Ratings

BenzingaMay 1 18:35

Buy Rating Affirmed for Lyra Therapeutics Amid Favorable LYR-210 Trial Outcomes and Strategic CRS Market Positioning

TipRanksMay 1 18:20

Buy Rating for Lyra Therapeutics Backed by Upcoming Catalysts and Market Potential

TipRanksMay 1 18:20

Lyra Therapeutics Analyst Ratings

BenzingaMar 25 18:50

HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target

BenzingaMar 22 18:45

Lyra Therapeutics Analyst Ratings

BenzingaMar 22 18:40

Optimistic Buy Rating for Lyra Therapeutics' LYR-210 Amidst Phase 3 Trial and Market Opportunity

TipRanksMar 22 18:25